As the US headquarters of German drug maker
, Boehringer Ingelheim Corporation oversees about half a dozen stateside subsidiaries that produce and sell drugs (both prescription and over-the-counter), animal health products, and chemicals for the US market. It sells its prescription and OTC products through its largest unit
Boehringer Ingelheim Pharmaceuticals
. Additionally, the firm's
(which the company is selling) makes generic drugs, and its
Ben Venue Laboratories
is a contract pharmaceutical manufacturer and provides drug development services to other pharmaceutical companies.
The company's Boehringer Ingelheim Vetmedica unit is a leading US maker of health products for farm animals and pets, while Boehringer Ingelheim Chemicals produces active pharmaceutical ingredients used in drugmaking.
Through its Pharmaceuticals subsidiary, Boehringer Ingelheim Corporation serves as one of its parent company's major research centers, with particular focus on cardiovascular disease, immunology, and inflammatory conditions.
Boehringer Ingelheim has a collaboration agreement with Evotec OAI and Evotec Neurosciences to jointly identify and develop small molecule therapies acting on selected G-Protein Coupled Receptors. Additionally, the company has a collaboration and license agreement with AbGenomics that gives Boehringer Ingelheim the global exclusive rights to develop, manufacture, and commercialize an AbGenomics therapeutic monoclonal antibody.
Geographic ReachThe company has operations in Ridgefield, Connecticut; Cleveland and Columbus, Ohio; St. Joseph, Missouri; and Fremont, California.
In 2014 Boehringer Ingelheim Pharmaceuticals and
approval for their Jardiance tablets to improve blood glucose levels in adults with type 2 diabetes. The FDA also approved Striverdi Respimat Inhalation Spray µg as a maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease. Other FDA-approved treatments include Pradaxa for the treatment of deep venous thrombosis and pulmonary embolism (2014) and Glyxambi tablets for the treatment of type 2 diabetes.
The company announced plans to lay off 724 employees across the US in 2016. The announcement comes amid a number of corporate restructurings such as the group's withdrawal from generics operations and an increased focus on animal health.